Previously, the research team — led by principal investigator Vera Moiseenkova-Bell, PhD — established TRPV2 is involved in outgrowth of sensory neurons which can cause potentially crippling chronic pain. It is also involved in malignancy in neuroblastomas, prostate cancer and bladder cancer.
By understanding the protein’s structure, the researchers may be able to develop new therapeutic treatments for chronic pain and malignant cancer cells.
“By combining our findings regarding both this protein’s structure and molecular mechanism, we can investigate it with a more holistic understanding,” said Dr. Moiseenkova-Bell. “This positions us to develop pharmaceutical compounds that target TRPV2 as treatment for chronic pain.”
More articles on chronic pain:
Stanford creates database to track health of chronic pain patients
ER physicians call for the removal of pain care questions from CAHPS surveys
New Jersey’s largest ER shares findings from Alternatives to Opiates program
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.